Latest Results

April 23, 2020

FY2020 1Q Consolidated Financial Overview

Financial Highlight

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
179,424 (61,272) (15,774) (26,100) (3,867)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
72,411 40.4 71,214 51,533 94.11

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
1,045,605 382,353 663,251 (24,280) (167,207)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Half-year dividends per share (yen)
854,118 27.3 81.7 -*1(Forecast) 75.00(Forecast)*2
  • *1 Effective July 1, 2020, three-for-one split of common stock will be implemented. The annual dividends per share forecast is not stated because the amounts cannot be simply combined. When calculated based on the assumption of no stock split, the year-end dividend forecast is ¥75 and the annual dividend per share forecast is ¥150.
  • *2 The amount prior to the stock split is presented.

Core results summary

  • Year-on-year increase in revenues and operating profit
  • Record-high Q1 revenues, operating profit and net income
  • Progress vs. full-year forecast in line with forecast
(Billions of JPY) 2020
Jan – Mar
Growth
(year on year)
Forecast on Jan. 30 Progress
Revenues 179.4 +25.1 +16.3% 24.2%
Cost of sales

cost to sales ratio

-61.0

42.2%

+2.7

-4.1%pts

-4.2% 24.2%
Operating expenses

Research and development

-44.4

-25.0

-1.7

-1.4

+4.0%

+5.9%

20.8%

21.7%

Operating profit

operating margin

74.1

41.3%

+26.2

+10.3%pts

+54.7% 26.9%
Net income 52.7 +16.4 +45.2% 26.2%
EPS (JPY) 96.11 +29.96 +45.3% 26.3%*3
  • *3 Progress is calculated excluding effect of the stock split. Common stock will be split three-for-one, with July 1, 2020 as the effective date.

Jan-Mar 2020 Sales

Graph of Jan-Mar 2020 Sales Oncology field 54.7 billion JPY (+ 5.2% y/y), Bone and joint diseases field 24.9 billion JPY (+ 2.9% y/y), Renal diseases field 6.7 billion JPY (-15.2% y/y), Other field 15.5 billion JPY (+ 2.0% y/y), Overseas 42.6 billion JPY (+ 10.9% y/y), Total 144.5 billion JPY

Core Operating Income Jan-Mar

Graph of Core Operating Income Jan-Mar 2020 Operating profit 74.1 billion JPY, Operating profit ratio 41.3% Jan-Mar 2019 Operating profit 47.9 billion JPY + 26.2 billion JPY (+54.7%) (Breakdown of increase / decrease: Gross profit from sales + 9.6 billion JPY, Royalties and other operating income + 18.3 billion JPY, M&D - 0.1 billion JPY, R&D - 1.4 billion JPY, G&A - 0.2 billion JPY)
  • *Amounts are rounded to the nearest 0.1 billion yen.
    Variance and % are calculated based on amounts shown.

More Information

Quarterly Reports

  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top